Comprehensive hormone panel

What it is

A comprehensive hormone panel — also called hormone bloodwork or a biomarker panel — is a single requisition that measures multiple hormones simultaneously, giving clinicians a cross-sectional snapshot of the endocrine system rather than a single isolated value. In Canada, roughly 1 in 5 adults will experience a clinically significant hormone disorder at some point in their lives, yet individual hormone tests ordered in isolation miss interactions between axes (e.g., how elevated cortisol suppresses thyroid-stimulating hormone). A comprehensive panel addresses that gap by capturing sex hormones, thyroid markers, adrenal output, and metabolic regulators in one draw.

The term "comprehensive hormone panel" has no single standardized definition across laboratories; what LifeLabs or Dynacare bundles under that label may differ from what an endocrinologist orders on a custom requisition. Panels are most commonly collected via serum (venipuncture), though dried urine testing and saliva sampling are used in specific clinical contexts.

Marker category	Common analytes	Primary clinical use
Sex hormones	Total testosterone, free testosterone, estradiol (E2), progesterone, DHEA-S	Hypogonadism, menopause, PCOS, fertility
Pituitary signals	LH, FSH, prolactin	Cycle irregularity, infertility workup
Thyroid axis	TSH, free T4, free T3, anti-TPO antibodies	Hypothyroidism, Hashimoto's, hyperthyroidism
Adrenal / stress	Cortisol (AM), DHEA-S	Adrenal insufficiency, HPA dysregulation
Metabolic anchors	Fasting insulin, HOMA-IR, SHBG	Insulin resistance, PCOS, metabolic syndrome
Binding proteins	SHBG, albumin	Calculating free hormone fractions

Sex hormone-binding globulin (SHBG) — a glycoprotein that controls the bioavailable fraction of sex hormones in circulation — is increasingly recognized as a marker of metabolic syndrome and cardiovascular risk beyond its traditional role in hormone transport, making it a valuable addition to any comprehensive panel.

Causes and mechanism

Hormones operate through feedback loops: the hypothalamus releases signalling peptides, the pituitary amplifies or dampens them, and peripheral glands (thyroid, adrenals, gonads) respond. Disruption at any node — autoimmune attack, aging, obesity, chronic stress, or medication — shifts the entire axis. A panel captures multiple nodes at once, which is why a single TSH result can look normal while free T3 is low, or why testosterone can appear adequate on total measurement but deficient once SHBG is factored in.

Hormone levels also vary by time of day, menstrual cycle phase, fasting status, and collection method. Cortisol peaks within 30–60 minutes of waking; testosterone is highest in the morning; progesterone is only interpretable relative to cycle day. These pre-analytical variables are a leading source of misinterpretation, and a 2021 review in the Journal of Clinical Endocrinology & Metabolism identified inconsistent collection timing as one of the most common laboratory pitfalls in hormone research and clinical practice.

Symptoms and diagnosis

Patients typically present with overlapping, non-specific symptoms: fatigue, weight changes, low libido, mood shifts, irregular periods, poor sleep, or hair thinning. Because these symptoms map onto multiple hormone axes simultaneously, a targeted single-hormone test often leaves the picture incomplete.

A clinician ordering a comprehensive panel will typically specify:

1. Timing instructions — morning draw (before 10 a.m.) for cortisol and testosterone; cycle day 2–5 for FSH/LH/estradiol in people with periods; day 19–22 for progesterone.
2. Fasting requirements — fasting insulin and glucose require an 8–12 hour fast; most sex hormones do not.
3. Medication holds — biotin (vitamin B7) at doses above 5 mg/day can falsely skew thyroid and other immunoassay results; patients are typically asked to hold it for 48–72 hours before the draw.

In Canada, most panels are processed through LifeLabs or Dynacare; turnaround is typically 3–7 business days for standard serum assays. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) — the gold-standard method for steroid hormones — is available at reference labs but not universally used for routine panels.

Treatment options

A comprehensive panel does not itself constitute treatment; it informs it. Depending on findings, a clinician may recommend:

• Thyroid hormone replacement (levothyroxine) for confirmed hypothyroidism — covered under most provincial drug benefit programs.
• Testosterone therapy (topical gel, injection, or pellet) for hypogonadism in men or women, available by prescription in Canada; coverage varies by province and indication.
• Menopausal hormone therapy (MHT) — estrogen with or without progesterone — guided by estradiol, FSH, and progesterone results, per SOGC's 2021 Menopause Guideline.
• Lifestyle and metabolic interventions for insulin resistance flagged by fasting insulin or HOMA-IR.
• Referral to endocrinology when results suggest pituitary pathology (e.g., elevated prolactin, suppressed LH/FSH with low sex hormones).

Follow-up panels are typically ordered 6–12 weeks after initiating therapy to confirm that target ranges have been reached.

When to see a clinician in Canada

A family physician can order most components of a comprehensive hormone panel under provincial health insurance (OHIP, MSP, AHCPB, etc.), though coverage for the full panel varies — some provinces cover only individual tests when a specific diagnosis code is attached. If a GP declines to order a full panel, patients can self-pay through LifeLabs or Dynacare direct-access testing in provinces that permit it (Ontario, BC, Alberta, and others).

Virtual hormone clinics operating in Canada — including Felix, Cleo, Phoenix, Maple, and Science & Humans — can requisition panels and interpret results online, which is useful for patients in rural or underserved areas. Regardless of platform, results should be reviewed by a licensed clinician, not interpreted solely from a lab reference range printout.

Seek prompt in-person care if results show very low sodium (possible SIADH), markedly elevated or suppressed cortisol (possible adrenal crisis or Cushing's), or prolactin above 200 µg/L (possible pituitary adenoma).

Limitations and open questions

Research is still emerging on optimal reference ranges for free testosterone and free estradiol, particularly in older adults and transgender patients on gender-affirming hormone therapy. Most published reference intervals were derived from relatively homogeneous populations and may not apply universally.

Saliva and dried urine testing are used in some integrative medicine contexts, but Health Canada has not issued formal guidance on their clinical equivalence to serum assays for most analytes. A 2021 PMC study found reasonable correlation between dried urine and serum for certain steroid metabolites, but variability remains a concern for clinical decision-making.

There is also no consensus on how frequently a "comprehensive" panel should be repeated in asymptomatic adults, or whether population-level screening is cost-effective. The Canadian Task Force on Preventive Health Care has not issued a recommendation on routine hormone screening in the absence of symptoms. Clinicians and patients should weigh the risk of incidental findings — values slightly outside reference range that trigger anxiety and further testing without clear clinical benefit.